source
- Servier’s $1.55 B Edgewise muscular dystrophy trial fails to meet primary and secondary endpointsServier invested roughly $1.55 billion in Edgewise Therapeutics' muscular dystrophy program and, five months after the deal, announced that the pivotal phase 2 trial in Becker muscular dystrophy di…
- Madrigal ex-clinical head sues, alleging liver-injury data cover-up for RezdiffraMadrigal Pharmaceuticals is being sued by its former senior vice president and head of clinical development, Michael Charlton, who claims senior leaders suppressed serious liver‑injury data for the…